Tremlett HL, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol 2004; 251: 1297-303.
Byrnes V., Afdhal N., Challies T., Greenstein PE Drug induced liver injury secondary to interferon-beta in multiple sclerosis. Ann Hepatol 2006; 5: 56-9.
Christopher V., Scolding N., Przemioslo RT Acute hepatitis secondary to interferon beta-1a in multiple sclerosis. J Neurol 2005; 252: 855-56.
Francis GS, Grumser Y., Alteri E., et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: Incidence and clinical significance. Drug Safety 2003; 26: 815-27.
Pietrosi G., Mandala L., Vizzini GB, et al. Fulminant hepatic failure and autoimmune disorders in patient with multiple sclerosis on interferon beta 1a: A fatal combination? Transpl Int 2008; 21: 502-04.
Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001; 56: 1416.
Lewis JH Hepatic toxicity of nonsteroidal antiinflammatory drugs. Drug Rev 1984; 3: 128-38.
Pulicken M., Koteish A., DeBusk K., Calabresi PA Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy. Neurology 2006; 66: 1954-55.
Neumann H., Csepregi A., Sailer M., Malfertheiner P. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis. J Neurol 2007; 254: 816-7.
von Kalckreuth V., Lohser AW, Schramm C. Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis - not only beta interferon. Am J Gastroenterol 2008; 103: 2147-48.
de Seze J., Canva-Delcambre V., Fajardy I., et al. Autoimmune hepatitis and multiple sclerosis: A coincidental association? Mult Scler 2005; 11: 691-3.
